Pazopanib multi target TKI

Description Results NMA

pazopanib in combination with pemetrexed (n=-9)

vs.

(n=-9)

open-label

Sample size: -9/-9

Primary endpoint: progression-free survival (PFS).

FU duration:

phase II

PFS 0.46 [0.34; 0.62]

PFS 0.46 [0.34; 0.62]

OS 0.91 [0.71; 1.16]

OS 0.91 [0.76; 1.08]

PFS 1.05 [0.90; 1.22]

pazopanib (n=-9)

vs.

placebo (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint: PFS

FU duration:

(n=290)

vs.

(n=145)

Sample size: 290/145

Primary endpoint: PFS

FU duration:

continuous dose of pazopanib (800 mg once daily) (n=557)

vs.

sunitinib in 6-week cycles (50 mg once daily for 4 weeks, followed by 2 weeks without treatment) (n=553)

Parallel groups

Sample size: 557/553

Primary endpoint: PFS

FU duration:

PFS 0.31 [0.24; 0.40]

OS 0.86 [0.67; 1.11]

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: